Kyowa Kirin International plc

kyowa-kirin.com

At Kyowa Kirin International plc “Commitment to Life” is at our core. With over 500 people focused on this purpose we’ve become a highly successful and rapidly growing specialty pharmaceutical company engaged in the development and commercialization of innovative medicines for the treatment of unmet therapeutic needs in major western markets. Kyowa Kirin International plc is owned by Kyowa Hakko Kirin Co., Ltd (KHK) of Japan. Founded in 1949, KHK has a successful track record in Japan and is now expanding globally. Our highly successful product portfolio, enviable pipeline and active Business Development group provides a wealth of products in the therapeutic areas of Oncology, CNS and Nephrology. With three key anti-body therapies in late stage development Kyowa Kirin is setting the scene for transformative growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Rhythm | December 01, 2020

news image

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More

RAPID NHS RESPONSE TEAMS TO HELP OLDER PEOPLE AT HOME

PharmaTimes | January 28, 2020

news image

The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...

Read More

Pharma Tech

JANSSEN SEEKS EUROPEAN COMMISSION APPROVAL OF A NEW INDICATION FOR CARVYKTI® FOR THE EARLIER TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY

Globenewswire | June 01, 2023

news image

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma. “The previous European Commission approval recognised the potential for cilta-cel to positively impact outcomes for peop...

Read More

Business Insights

TENDONOVA WINS FDA CLEARANCE FOR ITS NEW MICROINVASIVE OCELOT SURGICAL TOOL

TendoNova | March 24, 2022

news image

TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510 clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue. The FDA found the Ocelot TDS 1000 substantially equivalent to the Tenex TX1 which is routinely used for percutaneous tenotomy in orthopedics, sports medicine, pain management, and podiatry. The Ocelot System's form factor and price point make it an exciting ...

Read More
news image

Research

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Rhythm | December 01, 2020

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More
news image

RAPID NHS RESPONSE TEAMS TO HELP OLDER PEOPLE AT HOME

PharmaTimes | January 28, 2020

The NHS has announced new “expert rapid response teams” in order to help support older people to remain well at home and avoid hospital admissions. New plans outlined by the health service say that the teams will be able to be on hand within two hours, as part of the NHS’ Long Term Plan to support England’s ageing population and those with complex needs. Backed by £14 million of investment, local health service and council teams will begin the roll out of the servic...

Read More
news image

Pharma Tech

JANSSEN SEEKS EUROPEAN COMMISSION APPROVAL OF A NEW INDICATION FOR CARVYKTI® FOR THE EARLIER TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY

Globenewswire | June 01, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma. “The previous European Commission approval recognised the potential for cilta-cel to positively impact outcomes for peop...

Read More
news image

Business Insights

TENDONOVA WINS FDA CLEARANCE FOR ITS NEW MICROINVASIVE OCELOT SURGICAL TOOL

TendoNova | March 24, 2022

TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510 clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue. The FDA found the Ocelot TDS 1000 substantially equivalent to the Tenex TX1 which is routinely used for percutaneous tenotomy in orthopedics, sports medicine, pain management, and podiatry. The Ocelot System's form factor and price point make it an exciting ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us